Extended‐Interval Dosing and Discontinuation of Dupilumab in Atopic Dermatitis: A Real‐World Retrospective Study
Open Access
- 11 June 2026
- journal article
- research article
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (8) , 1179-1183
Abstract
This retrospective study evaluated the clinical courses and treatment patterns of 81 patients with atopic dermatitis (AD) treated with dupilumab at Hiroshima University Hospital. Patients were categorized into six groups based on their clinical outcomes, including those who continued treatment, achieved remission and discontinued, or discontinued due to adverse effects or insufficient efficacy. Of the 81 patients, 38 (47%) continued treatment throughout the study period, and 16 (20%) achieved remission and discontinued treatment without relapse. Analysis of baseline severity using EASI and TARC levels revealed no significant differences between these groups, suggesting that baseline severity does not predict long‐term therapeutic outcomes. Regarding concomitant topical therapy, although the potency of topical corticosteroids (TCS) remained unchanged in most patients, the total dosage was significantly reduced by a mean of 71.3%, reflecting a successful transition to proactive therapy or a reduced affected body surface area. Furthermore, this study investigated the feasibility of extending dupilumab dosing intervals. Nearly half of the patients extended their intervals including every 3 weeks (Q3W), Q4W, and up to Q8W by 6 months without exacerbation. By 12 months, 22 of the 40 evaluable patients successfully transitioned to extended intervals up to Q12W. These findings suggest that baseline disease severity does not necessarily predict the long‐term clinical course of dupilumab therapy in patients with AD. Although TCS potency is often maintained to ensure stability, the dosage can be drastically reduced. Furthermore, a subset of patients can discontinue or extend the dosing intervals, and the optimal timing for extending intervals is more flexible and can be initiated earlier than currently suggested by previous reports.Keywords
This publication has 10 references indexed in Scilit:
- Long‐Term Effectiveness of Dupilumab in Moderate‐to‐Severe Atopic Dermatitis Across Different Body Regions in Extended Dosing‐Interval Regimens: A Real‐World Chinese StudyExperimental Dermatology, 2025
- Appropriate Injection Intervals of Dupilumab in Patients With Adult Atopic Dermatitis: A Step Toward Developing Guidelines for Daily PracticeAnnals of Dermatology, 2025
- Biomarkers and patient-related factors associated with clinical outcomes in dupilumab-treated atopic dermatitisJournal of Allergy and Clinical Immunology: Global, 2024
- Extending dupilumab dosing intervals in atopic dermatitis: A prospective observational study in a South European tertiary hospitalJournal of the European Academy of Dermatology and Venereology, 2023
- Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registryBritish Journal of Dermatology, 2023
- Lengthening the time intervals between doses of dupilumab in remission atopic dermatitisJournal of the European Academy of Dermatology and Venereology, 2023
- Dupilumab dose spacing after initial successful treatment or adverse events in adult patients with atopic dermatitis: A retrospective analysisDermatologic Therapy, 2022
- Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitisAllergy, 2022
- Longer dupilumab dosing intervals in adult patients with atopic dermatitis: experience from a French multicentre retrospective cohort studyBritish Journal of Dermatology, 2022
- Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic DermatitisJAMA Dermatology, 2020